智通财经APP获悉，生物技术公司TScan Therapeutics(TCRX.US)周四宣布，将出售约3000万美元的预融资认股权证，能以每股4.00美元的价格购买总计不超过750万 ...

TScan Therapeutics Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company with a market capitalization of $139.57 million, is poised at a critical juncture in its development of innovative ...

TScan Therapeutics, Inc. (TCRX) has been on a downward spiral lately with significant selling pressure. After declining 5.6% over the past four weeks, the stock looks well positioned for a trend ...

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously ...

TScan Therapeutics (TCRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vikram Purohit from Morgan Stanley maintained a Buy rating ...

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...

TScan Therapeutics' stock rises after announcing a $30 million financing deal with Lynx1, extending its cash runway into 2027. Around $10M Bet On This Real Estate Stock? Check Out These 3 Penny ...

TScan Therapeutics has entered a new loan agreement with Silicon Valley Bank, securing up to $52.5 million to refinance existing debt and fund corporate purposes. This non-dilutive financing ...